• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然药物:趋势、特性及美国食品药品监督管理局批准数量的下降

Natural drugs: Trends, properties, and decline in FDA approvals.

作者信息

Rose Tyler M, Baranek Monika, Kaka Maryam, Shwani Sarah

机构信息

Roseman University of Health Sciences, College of Pharmacy, 10920 South River Front Parkway, South Jordan, UT 84095, USA.

出版信息

J Pharm Sci. 2025 Feb;114(2):782-786. doi: 10.1016/j.xphs.2024.12.007. Epub 2024 Dec 25.

DOI:10.1016/j.xphs.2024.12.007
PMID:39730033
Abstract

The purpose of this review is to better characterize the contribution and properties of FDA-approved drugs that can be found unmodified in nature. Defined inclusion criteria were applied to drugs identified in previous studies and in annual FDA approval reports to compile a comprehensive list of approved drugs found in nature. Databases and scientific literature were searched to identify chemical and drug properties of these entities, including chemical classes, approval years, drug indications, and approved delivery methods. A random sample of FDA-approved drugs not found in nature was also created for comparison. Drugs from nature are estimated to represent 5 % of FDA approved drugs. The most common classes of natural product drugs are alkaloids, oligopeptides, polyphenols, and polyketides. Approvals of unmodified drugs from nature have declined at a rate of about two per decade since the mid-1900s. Compared to non-natural drugs, drugs from nature are more likely to be used as antibacterials and for dermatological conditions. Natural drugs are also less likely to be delivered orally and more likely to have narrow therapeutic indexes. Given the limitations of unmodified natural products as drugs, the pharmaceutical sciences will likely continue to play an important role in improving the drug-likeness of natural scaffolds.

摘要

本综述的目的是更好地描述那些在自然界中可直接找到的、已获美国食品药品监督管理局(FDA)批准的药物的贡献和特性。将已定义的纳入标准应用于先前研究及FDA年度批准报告中所确定的药物,以编制一份自然界中已批准药物的综合清单。通过检索数据库和科学文献来确定这些药物的化学和药物特性,包括化学类别、批准年份、药物适应症以及批准的给药方式。还随机抽取了一些在自然界中未发现的、已获FDA批准的药物作为对照。据估计,来自自然界的药物占FDA批准药物的5%。天然产物药物最常见的类别是生物碱、寡肽、多酚和聚酮化合物。自20世纪中叶以来,未经修饰的天然药物的批准数量以每十年约两种的速度下降。与非天然药物相比,来自自然界的药物更有可能被用作抗菌药物以及用于皮肤病治疗。天然药物口服给药的可能性也较小,且更有可能具有较窄的治疗指数。鉴于未经修饰的天然产物作为药物存在局限性,药物科学可能会继续在改善天然药物骨架的类药性质方面发挥重要作用。

相似文献

1
Natural drugs: Trends, properties, and decline in FDA approvals.天然药物:趋势、特性及美国食品药品监督管理局批准数量的下降
J Pharm Sci. 2025 Feb;114(2):782-786. doi: 10.1016/j.xphs.2024.12.007. Epub 2024 Dec 25.
2
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.通过开发已批准药物的新用途进行创新:补充适应症营销批准的趋势。
Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28.
3
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.2017 年制药行业。从分子角度对 FDA 药物批准的分析。
Molecules. 2018 Feb 27;23(3):533. doi: 10.3390/molecules23030533.
4
The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.2023 年的制药行业:从分子角度分析 FDA 药物批准。
Molecules. 2024 Jan 25;29(3):585. doi: 10.3390/molecules29030585.
5
New drug approvals for 2021: Synthesis and clinical applications.2021 年新药批准:合成与临床应用。
Eur J Med Chem. 2023 Jan 5;245(Pt 1):114898. doi: 10.1016/j.ejmech.2022.114898. Epub 2022 Nov 4.
6
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.2022 年的制药行业:从分子角度分析 FDA 药物批准情况。
Molecules. 2023 Jan 20;28(3):1038. doi: 10.3390/molecules28031038.
7
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.2018 年制药行业。从分子角度分析 FDA 药物批准情况。
Molecules. 2019 Feb 23;24(4):809. doi: 10.3390/molecules24040809.
8
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.FDA 对药品的批准与监管,1983-2018 年。
JAMA. 2020 Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288.
9
Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.2017 年至 2019 年美国食品和药物管理局批准药品和生物制品补充适应症的临床研究特征。
JAMA Netw Open. 2021 Jun 1;4(6):e2113224. doi: 10.1001/jamanetworkopen.2021.13224.
10
An analysis of FDA-approved drugs: natural products and their derivatives.对美国食品药品监督管理局(FDA)批准药物的分析:天然产物及其衍生物。
Drug Discov Today. 2016 Feb;21(2):204-7. doi: 10.1016/j.drudis.2015.01.009. Epub 2015 Jan 21.

引用本文的文献

1
Significant Improvement in Bioavailability and Therapeutic Efficacy of Mebendazole Oral Nano-Systems Assessed in a Murine Model with Extreme Phenotypes of Susceptibility to .在对甲苯咪唑口服纳米系统的生物利用度和治疗效果进行评估的极端易感性小鼠模型中,其生物利用度和治疗效果有显著改善。
Pharmaceutics. 2025 Aug 19;17(8):1069. doi: 10.3390/pharmaceutics17081069.
2
Natural multi-active nanoparticles integrated biological hydrogel microcarriers for wound healing.用于伤口愈合的天然多活性纳米颗粒集成生物水凝胶微载体
J Nanobiotechnology. 2025 Aug 22;23(1):582. doi: 10.1186/s12951-025-03666-7.